Biogen Pharmachem Industries Limited has fulfilled its regulatory compliance requirements by submitting the mandatory quarterly certificate under SEBI regulations for the third quarter of fiscal year 2026. The pharmaceutical company, listed on BSE with scrip code 531752, completed this submission on January 5, 2026.

Regulatory Compliance Details

The certificate was submitted pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. This regulation mandates listed companies to provide quarterly confirmations regarding the dematerialization of physical share certificates.

Certificate Confirmation

Satellite Corporate Services Private Limited, serving as the company's Registrar & Share Transfer Agent, issued the compliance certificate. The certificate confirms adherence to standard regulatory requirements, including verification that securities are listed on stock exchanges and proper record maintenance procedures.

A significant aspect of this quarter's report is that no physical share certificates were received for dematerialization during Q3FY26. This indicates that shareholders did not submit any physical certificates for conversion to electronic form during the three-month period.

Company Information

Biogen Pharmachem Industries Limited operates under CIN L51100GJ1995PLC026702 and was formerly known as Sun Techno Overseas Limited. The company maintains its registered office at Shop No. 8, First Floor, Maker-1 Building, Jawahar Road, Rajkot-360001, Gujarat.

Regulatory Distribution

The certificate submission was distributed to relevant regulatory authorities and depositories as per standard compliance procedures:

• BSE Limited (primary listing exchange)
• National Securities Depository Limited (NSDL)
• Central Depository Services (India) Limited (CDSL)

This quarterly submission demonstrates the company's commitment to maintaining transparency and regulatory compliance in accordance with SEBI guidelines for listed entities.

Biogen Pharmachem Industries Limited , a pharmaceutical company based in Rajkot, has reported a remarkable turnaround in its financial performance for the first quarter. The company's unaudited financial results, approved by the Board of Directors on July 23, showcase a significant improvement in both revenue and profitability.

Financial Highlights

• Net Profit: Biogen Pharmachem reported a net profit of Rs 134.48 lakhs for the quarter, marking a substantial turnaround from a loss of Rs 15.83 lakhs in the same quarter last year.
• Revenue: Revenue from operations increased to Rs 154.28 lakhs, compared to a negative Rs 9.09 lakhs in the previous year's quarter.
• Expenses: Total expenses rose to Rs 19.80 lakhs from Rs 6.73 lakhs, primarily due to higher employee benefit expenses and other expenses.
• Earnings Per Share: Basic and diluted earnings per share stood at Rs 0.01.

Key Financial Metrics

Capital Structure and Other Details

• The company's paid-up equity share capital increased to Rs 9,026.03 lakhs from Rs 6,526.03 lakhs.
• The Board meeting to approve these results was held on July 23, commencing at 4:15 PM and concluding at 4:40 PM.

Auditor's Review

Rishi Sekhri and Associates, Chartered Accountants, conducted a limited review of the financial results. They stated that nothing has come to their attention that causes them to believe that the financial results do not present a true and fair view in accordance with applicable accounting standards and other recognized accounting practices and policies.

Conclusion

Biogen Pharmachem Industries Limited's quarterly results demonstrate a strong recovery and positive momentum. The company has successfully turned around its operations, moving from a loss-making position to achieving significant profitability. Investors and stakeholders will likely be watching closely to see if this positive trend continues in the coming quarters.